Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Sana Biotechnology, Inc.

Get SEC filing alerts via email and in your feed for Sana Biotechnology, Inc.

SANA

Sana Biotechnology, Inc.

About Sana Biotechnology, Inc.

Sana Biotechnology develops engineered cell therapies using ex vivo and in vivo platforms to treat diseases like type 1 diabetes, autoimmune disorders, and cancers. Its core focus is on hypoimmune, allogeneic cells that evade immune rejection, enabling off-the-shelf treatments. The company leverages stem cell technology, gene editing, and targeted delivery to create transformative therapies with broad applicability across multiple therapeutic areas.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Sana Biotechnology, Inc.

1
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $47.2 Million Net Loss in Q1 2026, Adjusts Development Focus

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $244.2 Million Net Loss for 2025, Focuses on SC451 and SG293 Programs

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $42.2 Million Net Loss in Q3 2025, Decreasing from Previous Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $93.8 Million Net Loss in Q2 2025, Adjusts Strategic Focus

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $49.4 Million Net Loss, Decreases Operating Expenses in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Sana Biotechnology, Inc. Sana Biotechnology Reports $266.76 Million Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Sana Biotechnology, Inc. Sana Biotechnology Reports Significant Net Loss and Restructuring Efforts in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments